top of page

VISION

Future-ready Cell Therapy

Allogenica is a preclinical biotech developing affordable immunotherapies in oncology for both solid and liquid tumors.

​

Allogenica's goal is to provide a universal, "off-the-shelf" cell therapy with the potential to treat all eligible patients with predictable safety and efficacy at drastically reduced manufacturing costs.

Allogenica's researchers
Allogenica’s unique CAR-T solution
cellcv.gif

A revolution in the field of cell therapy

Chimeric antigen receptor T-cell (CAR-T) therapy is one of the key therapies revolutionizing the healthcare landscape. The approach involves reprogramming immune cells to recognize and kill cancer cells.

 

But traditional CAR-T therapies, even when truly effective, are long and complex to manufacture, leading to delays that are often too long for patients battling life-threatening diseases.

Unlike traditional CAR-T therapies, Allogenica uses healthy donor hematopoietic stem cells and bioengineers them to express the CAR and treat the patient.

We are committed to making CAR-T therapies universal to bring new cancer treatments to the market that are immediately available to patients, safer and about 10 times less expensive to manufacture.

Our commitment

Inna MENKOVA

Inna MENKOVA, PhD

CEO and Co-founder of ALLOGENICA

Allogenica’s unique CAR-T solution
Allogenica’s unique CAR-T solution

Allogenica’s unique CAR-T solution

Allogenica has developed unique worldwide expertise:

WHY Allogenica

Our unique approach

Allogenica's unique know-how allows to differentiate stem cells into immature precursor T cells. Allogenica’s innovative CAR-containing vector allows to modify these cells to produce CAR-pre-T.

Allogenica’s most advanced drug candidate is expected to enter clinical trials in 2026.

hôpital

Allogenica’s CAR-T advantages:

  • High quality of start material

  • Great expansion capacity

  • No exhaustion markers

  • Potency assay

Advantages for bioproduction

bioproduction
Patient

  • No Graft vs Host disease (no TCR expression)

  • Long term persistence

  • Efficient thymic maturation

  • Potent anti-cancer activity

Therapeutic advantages

Allogenica’s bioproduction process consists in:

Transferring the CAR gene to these immature cells (called CAR-pre-T cells)

2

CAR-pre-T cells
stem cell from healthy donors

Harvesting stem cell from healthy donors

1

After production, CAR-pre-T cells are stored and ready to be delivered "off-the-shelf" when a patient needs them

4

CAR-pre-T cells are stored and ready to be delivered "off-the-shelf" when a patient needs them
Differentiate and expand the CAR-pre-T cells at large scale in a bioreactor

Differentiate and expand the CAR-pre-T cells at large scale in a bioreactor

3

Our Management Team

  • LinkedIn

Chief Executive Officer

and co-founder

Inna Menkova, PhD

  • LinkedIn

Chief Operations
Officer

Laure Vidalain

  • LinkedIn

Chief Development Officer

​

Tania Csaki

    Chief Scientific Officer

    ​

    To be announced

    Board of directors

    • LinkedIn

    Chairman of the BOD and co-founder

    Jean-Guillaume
    Lafay

    • LinkedIn

    Board member and co-founder

    Jean-Marie Grumel,
    MD

    • LinkedIn

    President at

    33 Californie

    Stephane Legastelois, PhD

    • LinkedIn

    Investment Manager Pulsalys

    Eglantine Rollet,
    PhD

    • LinkedIn

    Partner, Aloe Private Equity

    Jean Pascal
    Tranie

    Scientific Advisory Board

    1
    23

    Latest news

    Prof. Charles Dumontet,
    MD, PhD
    Chairman of the SAB

    • LinkedIn

    Prof. Olivier Adotevi,
    MD, PhD
     

    • LinkedIn

    Prof. Jean Daniel Lelièvre,
    MD, PhD
     

    • LinkedIn

    Julien Marie,
    PhD
     

    • LinkedIn

    COLLABORATIONS

    They support Allogenica

    DSCF7788-7.jpg

    Join our team

    bottom of page